Cargando…
Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
OBJECTIVES: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. METHODS: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse transcription-q...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278831/ https://www.ncbi.nlm.nih.gov/pubmed/34273511 http://dx.doi.org/10.1016/j.ijid.2021.07.014 |
_version_ | 1783722341209997312 |
---|---|
author | Markewitz, Robert Torge, Antje Wandinger, Klaus-Peter Pauli, Daniela Dargvainiene, Justina Franke, Andre Bujanda, Luis Marimón, José Maria Banales, Jesus M. Gutierrez-Stampa, María A. Nafría, Beatriz Junker, Ralf |
author_facet | Markewitz, Robert Torge, Antje Wandinger, Klaus-Peter Pauli, Daniela Dargvainiene, Justina Franke, Andre Bujanda, Luis Marimón, José Maria Banales, Jesus M. Gutierrez-Stampa, María A. Nafría, Beatriz Junker, Ralf |
author_sort | Markewitz, Robert |
collection | PubMed |
description | OBJECTIVES: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. METHODS: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse transcription-quantitative polymerase chain reaction) on admission were compared between 2 assays and correlated with the antibody response (in the course of the disease), the clinical course and the time since onset of symptoms. RESULTS: Ct values for 2 of 3 target genes showed significant differences between the 2 assays used (P=0.012 and P<0.0001). Ct values were significantly higher for antibody positive patients (P<0.0001) and positively correlated with the amount of time since onset of symptoms (R: 0.332–0.363; P<0.001). Patients with fatal outcomes showed higher viral loads than survivors (P<0.0001). CONCLUSIONS: Ct values depend strongly on assay used and target gene examined and should not be used as quantitative values to guide therapeutic or diagnostic decisions. The inverse association between antibody status and viral load suggests that antibodies contribute to the elimination of the virus, independent of the outcome, which is influenced by the viral load on admission and might depend more strongly on other parts of the immune response. |
format | Online Article Text |
id | pubmed-8278831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82788312021-07-20 Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region Markewitz, Robert Torge, Antje Wandinger, Klaus-Peter Pauli, Daniela Dargvainiene, Justina Franke, Andre Bujanda, Luis Marimón, José Maria Banales, Jesus M. Gutierrez-Stampa, María A. Nafría, Beatriz Junker, Ralf Int J Infect Dis Article OBJECTIVES: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. METHODS: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse transcription-quantitative polymerase chain reaction) on admission were compared between 2 assays and correlated with the antibody response (in the course of the disease), the clinical course and the time since onset of symptoms. RESULTS: Ct values for 2 of 3 target genes showed significant differences between the 2 assays used (P=0.012 and P<0.0001). Ct values were significantly higher for antibody positive patients (P<0.0001) and positively correlated with the amount of time since onset of symptoms (R: 0.332–0.363; P<0.001). Patients with fatal outcomes showed higher viral loads than survivors (P<0.0001). CONCLUSIONS: Ct values depend strongly on assay used and target gene examined and should not be used as quantitative values to guide therapeutic or diagnostic decisions. The inverse association between antibody status and viral load suggests that antibodies contribute to the elimination of the virus, independent of the outcome, which is influenced by the viral load on admission and might depend more strongly on other parts of the immune response. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-09 2021-07-14 /pmc/articles/PMC8278831/ /pubmed/34273511 http://dx.doi.org/10.1016/j.ijid.2021.07.014 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Markewitz, Robert Torge, Antje Wandinger, Klaus-Peter Pauli, Daniela Dargvainiene, Justina Franke, Andre Bujanda, Luis Marimón, José Maria Banales, Jesus M. Gutierrez-Stampa, María A. Nafría, Beatriz Junker, Ralf Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region |
title | Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region |
title_full | Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region |
title_fullStr | Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region |
title_full_unstemmed | Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region |
title_short | Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region |
title_sort | analysis of sars-cov-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-sars-cov-2 antibodies from a high incidence region |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278831/ https://www.ncbi.nlm.nih.gov/pubmed/34273511 http://dx.doi.org/10.1016/j.ijid.2021.07.014 |
work_keys_str_mv | AT markewitzrobert analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT torgeantje analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT wandingerklauspeter analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT paulidaniela analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT dargvainienejustina analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT frankeandre analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT bujandaluis analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT marimonjosemaria analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT banalesjesusm analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT gutierrezstampamariaa analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT nafriabeatriz analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT junkerralf analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion |